BiotechTubeBiotechTube
Home/Pipeline/CHS-006

CHS-006

Advanced solid tumors

Phase 1ActiveNCT05777300

Key Facts

Indication
Advanced solid tumors
Phase
Phase 1
Status
Active
Company
Coherus BioSciences

About Coherus BioSciences

Coherus BioSciences leverages its expertise in biologics development and commercialization to bring biosimilar and novel cancer therapies to market. The company has successfully launched UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar to Humira®, establishing a commercial foundation. Its strategic focus has expanded to include a promising immuno-oncology pipeline, most notably the clinical-stage anti-TIGIT antibody, toripalimab, acquired from Junshi Biosciences, positioning Coherus for future growth in the competitive oncology landscape.

View full company profile

Therapeutic Areas

OncologyImmunologyInflammatory Diseases

Other Advanced solid tumors Drugs

DrugCompanyPhase
SHR-1701Jiangsu Hengrui MedicinePhase 1
BAY 1895344BayerPhase 1
HS-10342Hansoh PharmaPhase 1/2
ANKTIVA® + M-ceNKImmunityBioPhase 1
DFTX-101Definium TherapeuticsPhase 1/2
REC-617Recursion PharmaceuticalsPhase 1/2
ZW220ZymeworksPreclinical
NX-1607Nurix TherapeuticsPhase 1a
IMA402 (TCR Bispecific)ImmaticsPhase 1
IMA403 (TCR Bispecific)ImmaticsPre-clinical
BCA101Bicara TherapeuticsPhase 1
AN4005Adlai NortyePreclinical